Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but various areas of management still lack high …

Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Early detection and management of prostate cancer has evolved over the past decade, with
a focus now on harm minimisation and reducing overdiagnosis and overtreatment, given the …

Androgen deprivation therapy (ADT) has been the main management strategy for prostate
cancer for more than eight decades, nowadays achieved commonly by administration of …

Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its
dynamics and continuous changes under external pressure, it is one of the major causes of …

Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …

Importance Although several cancer drugs receive US Food and Drug Administration (FDA)
approval each month, it is unclear how many of these cancer drugs transform the treatment …

Background Rezvilutamide, a novel androgen-receptor inhibitor with low blood–brain barrier
penetration, has shown potent antitumour activity against metastatic castration-resistant …

Purpose: Intensification of androgen deprivation therapy (ADT) with either docetaxel or
androgen receptor axis–targeted therapies (ARAT) are the current standard of care for …

Importance Although quality of life (QOL) is an important clinical end point, cancer drugs are
often approved based on overall survival (OS) or putative surrogate end points such as …